Floatz logo

ibi305

EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer

Innovent Biologics (Suzhou) Co. Ltd.monoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer cohort.

Asset / SponsorPhaseRating
ibi363
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2CCC

Same molecule, other indications

ibi305 is also rated in:

hepatocellular carcinomaDormant
B
Indicative ·
60 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
58 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →